The European Medicines Agency (EMA) has approved its fifth COVID-19 vaccine for distribution, granting conditional marketing authorisation for the two-dose vaccine.
The Nuvaxovid vaccine, manufactured by United States pharmaceutical company ‘Novavax’ may be applied to willing individuals aged 18 and over after it is give the green light from the European Union’s executive commission. It will join the Pfizer-BioNTech, Moderna, Johnson & Johnson and Astrazeneca vaccines within the EU.
The European Union has since ordered 100 million doses of the Novavax vaccine, with plans to buy another 100 million units in the near future as Europe continues to struggle with the recent surge in COVID-19 cases. Initial clinical trials carried out in the United States and Mexico found that the vaccine had 90.4% efficacy against COVID-19 cases while second trials in the UK showed 89.7% efficacy.
What do you make of this?
#MaltaDaily